Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06356272 · ClinicalTrials.gov registry record
Oropharynx (OPX) Biomarker Trial
A clinical trial of Head and Neck Carcinoma and Oropharyngeal Squamous Cell Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 440
- Enrollment target
- 1
- Study location
NCT06356272: Recruiting study of Head and Neck Carcinoma and Oropharyngeal Squamous Cell Carcinoma, sponsored by Mayo Clinic.
NCT06356272 is a study of Head and Neck Carcinoma and Oropharyngeal Squamous Cell Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 440 participants, above the 399-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06356272, a study of Head and Neck Carcinoma and Oropharyngeal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 440 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.
Primary Outcome
Biospecimen samples will be assessed for a biomarker (or biomarkers) that is present when disease is present (i.e., at diagnosis or recurrence) and not present when disease is absent (i.e., after treatment, in HPV negative patients or in normal controls).
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2029-11-30 |
What NCT06356272 shows while recruiting
NCT06356272 is an observational study that tracks outcomes without assigning an intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 399-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (10% higher).
The record links to 10 conditions, with Head and Neck Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06356272 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06356272 about?
NCT06356272 is a clinical study titled "Oropharynx (OPX) Biomarker Trial". The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.
What is the current status of trial NCT06356272?
This trial is currently recruiting. The enrollment target is 440 participants. The study started on 2019-11-15. Estimated completion is 2029-11-30.
What conditions does trial NCT06356272 study?
This clinical trial studies the following conditions: Head and Neck Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06356272?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06356272?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06356272 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06356272's enrollment target sits among peer trials
440 6th of 30 higher than 25 of 30 other Head and Neck Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patients, Financial Compass Trial
RECRUITING · NA
-
Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer
RECRUITING · NA
-
Cancer Genetic Testing in Ethnic Populations
RECRUITING · NA
-
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI